News

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of additional...

read more

IonOpticks’ Custom Chromatography Column to Become Biognosys’ Standard for High-Quality Proteomic Insights

Melbourne | Zurich 05 December 2024: Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonOpticks will supply Biognosys with custom chromatography columns to support the standardisation of its research services...

read more

evitria Partners with Sapio Sciences to Streamline Antibody Workflow Management and Reporting

BALTIMORE--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic Lab Notebook (ELN) and Sapio Report Builder to enhance its sample tracking, data capture, and reporting capabilities. Zurich-based evitria has established itself as a premier CHO-based transient expression services provider for...

read more

DINAMIQS welcomes two new leadership team members

Franziska Riesen Fuchs joins as Head Operational Readiness. Dr. Franziska Riesen Fuchs has over 20 years of experience in the pharma and CDMO industry. Prior to joining DINAMIQS, she held different strategic and operational functions at Lonza and Roche, including QA, manufacturing and external manufacturing positions. In addition, she has experience...

read more

Kuros Biosciences Expands into Extremities Markets

Schlieren (Zurich), Switzerland, November 19, 2024 – Kuros Biosciences (“Kuros”), a global leader in advanced bone healing technologies, today announced its strategic expansion into the extremities markets with the appointment of Jantzen Cole as Vice President of Market Development, Extremities, as well as the formation of a dedicated Surgeon Advisory...

read more